Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

Azelaprag / BGE-105.

Research draft

Azelaprag, also called BGE-105, is an experimental small-molecule apelin-receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Azelaprag, also called BGE-105, is an experimental small-molecule apelin-receptor agonist.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It targets apelin signalling implicated in muscle and metabolic physiology.

Human research

Human development occurred, but the STRIDES combination trial was discontinued after liver-enzyme elevations.

Preclinical & other research

Cell and animal research investigated muscle and metabolic effects.

Safety & unknowns

The liver-safety signal is material and should remain visible alongside efficacy claims.

Regulatory status

Discontinued trial status is documented by the developer; current programme status needs a separate check.

Reported use & evidence

Research profile draft

The supplied Azelaprag / BGE-105 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds